Aflibercept (Eylea, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA), the newest anti-VEGF agent, was approved by the FDA for the treatment of wet AMD in 2011 [10]. This evidence concerns the gene VEGFA and wet macular degeneration.